GSK Reports Results of Nucala (mepolizumab) in P-III Study for Hypereosinophilic Syndrome
Shots:
- The P-III study involve assessing Nucala (300mg- q4w- SC) vs PBO in 108 adolescent and adult patients with severe HES for 32wks.
- The P-III study results: met its 1EPs i.e- reduction in flares with 50% fewer patients experiencing HES flare (56% vs 28%). 2EPs: 66% lower risk of first HES flare; 66% reduction in the annualized rate of HES flares; improvement in fatigue score; safety results were consistent with the known profile of Nucala
- Nucala is mAb targeting IL-5- first treatment demonstrating a reduction in flares in HES and has received the FDA & EMA’s ODD to treat HES with its anticipated regulatory submission in 2020
Click here to read full press release/ article
Ref: GSK | Image: GSK
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com